Reported Reactions

Drugs

Generic name

Methamphetamine hydrochloride: adverse event reports filed with FDA

985 reports list it as a suspect or interacting product, 2006–2026.

985
reports as suspect product
0% of all reports · about 48 a year
57
reports, 12 months to June 2026
80 in the 12 months before
94.9%
marked serious by the reporter
57.4% across all reports
73.9%
record death among outcomes, as reported
728 reports · not verified by FDA

Between March 2006 and June 2026, 985 adverse event reports received by FDA list methamphetamine hydrochloride, a generic name as a suspect or interacting product. Reports that mention it only as a concomitant medication (88) are left out of every figure here.

In the 12 months to June 2026, 57 reports listed it, down 29% from 80 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 48 reports a year and 0% of the 20,646,523 reports in the database. How many people take it is not in the data, so a count is not a rate of occurrence.

The MedDRA terms listed most often are toxicity to various agents (25.3%), drug abuse (22.7%) and completed suicide (8.8%). A report can list several reactions, so shares add to more than 100%; 221 different terms appear across these reports. Toxicity to various agents is recorded in 25.3% of these reports, against 0.8% of all reports in the database.

94.9% of the reports are marked serious by the reporter; 73.9% record death among the outcomes and 14.4% record hospitalisation, as reported. 46.4% of the reports came from physicians, and the largest patient age group is 18 to 44 (55.7%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

04998Jul 2021: 0Aug 2021: 0Sep 2021: 2Oct 2021: 1Nov 2021: 1Dec 2021: 62022Jan 2022: 8Feb 2022: 98Mar 2022: 49Apr 2022: 22May 2022: 1Jun 2022: 0Jul 2022: 4Aug 2022: 1Sep 2022: 3Oct 2022: 15Nov 2022: 0Dec 2022: 02023Jan 2023: 19Feb 2023: 31Mar 2023: 2Apr 2023: 3May 2023: 3Jun 2023: 4Jul 2023: 7Aug 2023: 2Sep 2023: 7Oct 2023: 5Nov 2023: 1Dec 2023: 52024Jan 2024: 9Feb 2024: 0Mar 2024: 1Apr 2024: 0May 2024: 1Jun 2024: 20Jul 2024: 1Aug 2024: 8Sep 2024: 3Oct 2024: 2Nov 2024: 36Dec 2024: 72025Jan 2025: 11Feb 2025: 3Mar 2025: 2Apr 2025: 5May 2025: 1Jun 2025: 1Jul 2025: 4Aug 2025: 6Sep 2025: 4Oct 2025: 6Nov 2025: 4Dec 2025: 42026Jan 2026: 7Feb 2026: 13Mar 2026: 1Apr 2026: 1May 2026: 2Jun 2026: 5

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

01012012006: 3520062007: 322008: 222009: 2920092010: 362011: 1382012: 9720122013: 32014: 102015: 520152016: 152017: 72018: 1320182019: 352020: 292021: 2120212022: 2012023: 892024: 8820242025: 512026: 29

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Methamphetamine hydrochloride reports recording the termall reports in the database

  1. Toxicity to various agentspoisoning or toxic effect of one or more substances25.3%249
  2. Drug abusemisuse of a medicine22.7%224
  3. Completed suicidedeath by suicide8.8%87
  4. Deaththe patient died; cause not stated by this term8.3%82
  5. Cardiac arrestthe heart stopped6.9%68
  6. Drug interactionan interaction between medicines6.6%65
  7. Respiratory arrestbreathing stopped6.3%62
  8. Cardio-respiratory arrestthe heart and breathing stopped4.5%44
  9. Overdosea dose above the recommended amount4%39
  10. Serotonin syndrometoo much serotonin activity, with agitation, fever and tremor3%30
  11. Pulmonary oedemafluid in the lungs2.6%26
  12. Respiratory depressionslow or shallow breathing2.4%24
  13. Aggressionaggressive behaviour2.3%23
  14. Drug dependencedependence on a medicine1.7%17
  15. Poisoning1.7%17
  16. Exposure to toxic agent1.6%16
  17. Hepatitis Chepatitis C infection1.6%16
  18. Inappropriate schedule of product administrationthe product was taken at the wrong times1.5%15
  19. Road traffic accidenta road accident1.5%15
  20. Accidental overdosean accidental overdose1.4%14
  21. Rhabdomyolysismuscle breakdown1.4%14
  22. Foetal exposure during pregnancythe unborn baby was exposed to the medicine1.3%13
  23. Pneumonialung infection1.3%13
  24. Product dose omission issuea dose was missed1.3%13
  25. Substance use1.3%13

Top 30 of 221 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the share of all reports in the database; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Death73.9%728
Life-threatening1.1%11
Hospitalisation (initial or prolonged)14.4%142
Disability0.8%8
Congenital anomaly0.2%2
Other serious47.2%465
Not serious5.1%50

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 20,646,523 reports. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Patient age

Under 20.5%5
2 to 110.1%1
12 to 172.5%25
18 to 4455.7%549
45 to 6423.9%235
65 to 743.4%33
75 and over0%0
Age not given13.9%137

Patient sex

Female32.5%320
Male53.6%528
Not given13.9%137

Who reported

Physician46.4%457
Pharmacist2.6%26
Other health professional32.3%318
Lawyer0.7%7
Consumer or non-health professional13.2%130
Not given4.8%47

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 71.4% of reports give the United States as the country of the event or reporter.

Reason for use recorded

Indication as recorded (MedDRA)ReportsShare
Drug abuse454.6%
Suicide attempt90.9%
Drug abuser80.8%
Attention deficit/hyperactivity disorder70.7%
Completed suicide40.4%
Intentional drug misuse20.2%

The indication field is filled in by the reporter and is often blank; shares are of all 985 reports.

In context

MeasureMethamphetamine hydrochlorideAll reports
Reports as suspect product98520,646,523
Share of that pool—0%
Reports, latest 12 months571,332,454
Marked serious94.9%57.4%
Death recorded among outcomes, per 1,000 reports73991
Hospitalisation recorded, per 1,000 reports144213
Consumer-filed share13.2%45.8%
Top term, share of reportsToxicity to various agents 25.3%0.8%

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Questions about Methamphetamine hydrochloride reports

How many adverse event reports has FDA received for Methamphetamine hydrochloride?

985 reports list Methamphetamine hydrochloride as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 57 of them arrived in the latest 12 months. Another 88 list it only as a concomitant medication.

What reactions are recorded in Methamphetamine hydrochloride reports?

toxicity to various agents (25.3%), drug abuse (22.7%), completed suicide (8.8%), death (8.3%) and cardiac arrest (6.9%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Methamphetamine hydrochloride was responsible.

How serious are the reports?

94.9% are marked serious by the reporter. Among the outcomes recorded, 73.9% of reports include death and 14.4% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.

Who files these reports?

physician (46.4%), other health professional (32.3%) and consumer or non-health professional (13.2%). Most reports reach FDA through the manufacturer, which must forward reports it receives.

Are reports for Methamphetamine hydrochloride rising?

57 reports in the 12 months to June 2026, down 29% from 80 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.

Do these reports show that Methamphetamine hydrochloride was responsible for these reactions?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.

Is this a list of the side effects of Methamphetamine hydrochloride?

No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.

How do I report an adverse event?

Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Methamphetamine hydrochloride as a suspect or interacting product; reports listing it only as a concomitant medication (88) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.